Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - Syntrix Biosystems

Drug Profile

Research programme: small molecule therapeutics - Syntrix Biosystems

Alternative Names: Multidrug-resistant tuberculosis therapy; SX-576

Latest Information Update: 07 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntrix Biosystems
  • Developer Syntrix Biosystems; University of Toronto
  • Class Amides; Antiasthmatics; Antibacterials; Antituberculars; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Dihydrofolate synthetase inhibitors; Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Lung disorders; Tuberculosis

Most Recent Events

  • 07 Feb 2019 No development reported - Preclinical for Asthma in USA (PO) Syntrix Biosystems pipeline, February 2019
  • 16 May 2017 Syntrix Biosystems plans a phase I trial for SX 682 in combination with pembrolizumab in Melanoma (Late-stage disease, Metastatic disease, Combination therapy) in USA (NCT03161431)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top